Market Overview:
The global premature ejaculation treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of premature ejaculation, rising awareness about available treatments, and growing demand for effective and safe treatments. Based on type, the global premature ejaculation treatment market is segmented into antidepressants (SSRIs), phosphodiesterase-5 inhibitors (PDE-5 inhibitors), topical anesthetics, analgesics, and other treatments. The antidepressants (SSRI) segment is expected to account for the largest share of the global premature ejaculation treatment market in 2018. This can be attributed to their high efficacy and safety profile. Based on application, the global premature ejaculation treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. The hospital pharmacies segment is expected to account for the largest share of the global premature ejaculation treatment market in 2018.
Product Definition:
Premature ejaculation is a common sexual problem. It is defined as uncontrolled ejaculation either before or shortly after vaginal penetration, before the person wishes it, and with minimal stimulation. Premature ejaculation can be caused by psychological factors such as anxiety or guilt, by biological factors such as hormone levels or nerve damage, or by certain medications. It can also be a learned response from frequent masturbation or intercourse.
Antidepressants(SSRIs):
Antidepressants are the class of drugs used to treat depression. They work by increasing the amount of serotonin in the brain, thereby making the user feel better. The two most commonly prescribed antidepressants are SSRIs and SNRIs.
SSRIs include Fluoxetine (Prozac), Paroxetine (Paxil), Sertindole (Lescol), and Escitalopram (Esc).
Phosphodiesterase-5 Inhibitors:
Phosphodiesterase-5 (PDE-5) inhibitors are drugs that prevent the breakdown of cyclic adenosine monophosphate (cAMP), which leads to the inhibition of PDE-5. The main function of phosphodiesterase is to regulate the amount of cAMP in cells by controlling its hydrolysis and rephosphorylation.
Application Insights:
Based on application, the global premature ejaculation treatment market is segmented into partner therapy, self-treatment and others. The self-treatment segment held the largest share in 2016 owing to growing awareness about PE among men of all age groups. Partner therapy is expected to be the fastest growing segment due to rising prevalence of sexual dysfunction among both males and females across various regions. Premature ejaculation is not only a male issue; it also affects one's relationship with his partner as she often gets irritated during sex because of this condition. Thus, many couples opt for treatments that can help them last longer in bed without getting aroused so easily or having an orgasm after a few strokes.
The other category includes products used for treating impotence or erectile dysfunction (ED).
Regional Analysis:
Europe dominated the global premature ejaculation treatment market in 2018. The presence of well-established healthcare facilities and high prevalence of PE are some factors responsible for its large share. In addition, the availability of highly advanced products is anticipated to drive demand over the forecast period. According to a study published in International Journal Of Impotence Research, around 50% - 80% men between 30 and 39 years suffer from PE on regular basis while 7% - 10% men experience it every day.
The Asia Pacific is expected to witness fastest growth during forecast period owing to rising awareness about various treatment options available for this condition as well as growing number of patients seeking medical help for premature ejaculation problems due to stigma attached with this condition in India & China & Japan (ICPJ).
Growth Factors:
- Increasing awareness about premature ejaculation and its treatment options among people.
- Growing number of men suffering from premature ejaculation and seeking treatment for the same.
- Rising demand for effective and safe premature ejaculation treatments.
- Availability of a wide range of premature ejaculation treatments options at affordable prices.
Scope Of The Report
Report Attributes
Report Details
Report Title
Premature Ejaculation Treatment Market Research Report
By Type
Antidepressants(SSRIs), Phosphodiesterase-5 Inhibitors, Topical Anesthetics, Analgesics, Other Treatment
By Application
Global Premature Ejaculation Treatment Market Share by Distribution Channel: 2016 VS 2021 VS 2027, Hospital, Retail Pharmacy, Online Pharmacy, Other
By Companies
Pfizer, Novartis, Eli Lilly, Johnson & Johnson, GlaxoSmithKline, Bayer, Menarini, Teva, Sunrise Pharma, Regent Pacific, Torrent Pharma, Vivus
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
221
Number of Tables & Figures
155
Customization Available
Yes, the report can be customized as per your need.
Global Premature Ejaculation Treatment Market Report Segments:
The global Premature Ejaculation Treatment market is segmented on the basis of:
Types
Antidepressants(SSRIs), Phosphodiesterase-5 Inhibitors, Topical Anesthetics, Analgesics, Other Treatment
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Global Premature Ejaculation Treatment Market Share by Distribution Channel: 2016 VS 2021 VS 2027, Hospital, Retail Pharmacy, Online Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Eli Lilly
- Johnson & Johnson
- GlaxoSmithKline
- Bayer
- Menarini
- Teva
- Sunrise Pharma
- Regent Pacific
- Torrent Pharma
- Vivus
Highlights of The Premature Ejaculation Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antidepressants(SSRIs)
- Phosphodiesterase-5 Inhibitors
- Topical Anesthetics
- Analgesics
- Other Treatment
- By Application:
- Global Premature Ejaculation Treatment Market Share by Distribution Channel: 2016 VS 2021 VS 2027
- Hospital
- Retail Pharmacy
- Online Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Premature Ejaculation Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Premature ejaculation treatment is a medical procedure that is used to treat premature ejaculation. It involves the use of medications or devices to help delay or prevent orgasm.
Some of the major players in the premature ejaculation treatment market are Pfizer, Novartis, Eli Lilly, Johnson & Johnson, GlaxoSmithKline, Bayer, Menarini, Teva, Sunrise Pharma, Regent Pacific, Torrent Pharma, Vivus.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Premature Ejaculation Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Premature Ejaculation Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Premature Ejaculation Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Premature Ejaculation Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Premature Ejaculation Treatment Market Size & Forecast, 2020-2028
4.5.1 Premature Ejaculation Treatment Market Size and Y-o-Y Growth
4.5.2 Premature Ejaculation Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Antidepressants(SSRIs)
5.2.2 Phosphodiesterase-5 Inhibitors
5.2.3 Topical Anesthetics
5.2.4 Analgesics
5.2.5 Other Treatment
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Global Premature Ejaculation Treatment Market Share by Distribution Channel: 2016 VS 2021 VS 2027
6.2.2 Hospital
6.2.3 Retail Pharmacy
6.2.4 Online Pharmacy
6.2.5 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Premature Ejaculation Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Premature Ejaculation Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Antidepressants(SSRIs)
9.6.2 Phosphodiesterase-5 Inhibitors
9.6.3 Topical Anesthetics
9.6.4 Analgesics
9.6.5 Other Treatment
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Global Premature Ejaculation Treatment Market Share by Distribution Channel: 2016 VS 2021 VS 2027
9.10.2 Hospital
9.10.3 Retail Pharmacy
9.10.4 Online Pharmacy
9.10.5 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Antidepressants(SSRIs)
10.6.2 Phosphodiesterase-5 Inhibitors
10.6.3 Topical Anesthetics
10.6.4 Analgesics
10.6.5 Other Treatment
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Global Premature Ejaculation Treatment Market Share by Distribution Channel: 2016 VS 2021 VS 2027
10.10.2 Hospital
10.10.3 Retail Pharmacy
10.10.4 Online Pharmacy
10.10.5 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Antidepressants(SSRIs)
11.6.2 Phosphodiesterase-5 Inhibitors
11.6.3 Topical Anesthetics
11.6.4 Analgesics
11.6.5 Other Treatment
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Global Premature Ejaculation Treatment Market Share by Distribution Channel: 2016 VS 2021 VS 2027
11.10.2 Hospital
11.10.3 Retail Pharmacy
11.10.4 Online Pharmacy
11.10.5 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Antidepressants(SSRIs)
12.6.2 Phosphodiesterase-5 Inhibitors
12.6.3 Topical Anesthetics
12.6.4 Analgesics
12.6.5 Other Treatment
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Global Premature Ejaculation Treatment Market Share by Distribution Channel: 2016 VS 2021 VS 2027
12.10.2 Hospital
12.10.3 Retail Pharmacy
12.10.4 Online Pharmacy
12.10.5 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Antidepressants(SSRIs)
13.6.2 Phosphodiesterase-5 Inhibitors
13.6.3 Topical Anesthetics
13.6.4 Analgesics
13.6.5 Other Treatment
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Global Premature Ejaculation Treatment Market Share by Distribution Channel: 2016 VS 2021 VS 2027
13.10.2 Hospital
13.10.3 Retail Pharmacy
13.10.4 Online Pharmacy
13.10.5 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Premature Ejaculation Treatment Market: Competitive Dashboard
14.2 Global Premature Ejaculation Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Eli Lilly
14.3.4 Johnson & Johnson
14.3.5 GlaxoSmithKline
14.3.6 Bayer
14.3.7 Menarini
14.3.8 Teva
14.3.9 Sunrise Pharma
14.3.10 Regent Pacific
14.3.11 Torrent Pharma
14.3.12 Vivus
